Skip to content
2000
Volume 22, Issue 2
  • ISSN: 1573-4110
  • E-ISSN: 1875-6727

Abstract

Objective

This review article aims to provide crucial insights related to the chemistry, pharmacology and analytical techniques associated with Lobeglitazone, a promising anti-diabetic molecule. Diabetes is a chronic ailment which hinders the normal functioning of beta pancreatic cells due to which the pancreas becomes incapable of producing sufficient amount of insulin or the body is not able to utilize the insulin that is produced by the beta-pancreatic cells. Lobeglitazone is a novel thiazolidinedione class of drug approved for type-II diabetes management by regulatory agencies in South Korea and India. The molecule has the potential to replace pioglitazone for the treatment of type-II diabetes due to its lower effective dose (0.5 mg) and better safety profile.

Methods

A comprehensive literature review was conducted using sources like PubMed, ScienceDirect, and Google Scholar. The review focused on chemistry, pharmacology, efficacy, safety, and advancements in analytical techniques for Lobeglitazone estimation in biological samples, bulk, and dosage forms.

Results

Lobeglitazone exhibits potent therapeutic efficacy in treating type-II diabetes with fewer adverse effects compared to previous thiazolidinedione drugs. It demonstrates a better safety profile, especially in terms of cardiovascular risk. However, current analytical methods for lobeglitazone rely on solvents that do not adhere to green chemistry principles, highlighting the need for eco-friendly alternatives.

Conclusion

Lobeglitazone holds substantial potential to replace older thiazolidinedione drugs due to its lower effective dose and improved safety profile. Future research should focus on developing sustainable analytical methods that align with green chemistry principles, further reinforcing its role in diabetes management.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cac/10.2174/0115734110331672241216040932
2025-01-02
2026-03-02

  • From This Site

    /content/journals/cac/10.2174/0115734110331672241216040932
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SapraA. BhandariP. Diabetes.StatPearlsStatPearls PublishingTreasure Island (FL)2023
     [Google Scholar]
  2. Facts & figures.Available from: https://idf.org/about-diabetes/diabetes-facts-figures/
  3. TaylorR.B. Diabetes mellitus: Type 1, type 2, and gestational diabetes.2021Available from: https://www.webmd.com/diabetes/types-of-diabetes-mellitus
  4. ZimmetP.Z. MaglianoD.J. HermanW.H. ShawJ.E. Diabetes: A 21st century challenge.Lancet Diabetes Endocrinol.201421566410.1016/S2213‑8587(13)70112‑824622669
     [Google Scholar]
  5. KahnC.R. Banting lecture. insulin action, diabetogenes, and the cause of type II diabetes.Diabetes19944381066108510.2337/diab.43.8.10668039601
     [Google Scholar]
  6. UnnikrishnanR. AnjanaR.M. MohanV. Diabetes mellitus and its complications in India.Nat. Rev. Endocrinol.201612635737010.1038/nrendo.2016.5327080137
     [Google Scholar]
  7. DeyL. AtteleA.S. YuanC-S. Alternative therapies for type 2 diabetes.Altern. Med. Rev.200271455811896745
     [Google Scholar]
  8. HanefeldM. PfütznerA. ForstT. LübbenG. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: A 42-month, open-label, observational, primary care study.Curr. Med. Res. Opin.20062261211121510.1185/030079906X11259816846554
     [Google Scholar]
  9. KahnS.E. HaffnerS.M. HeiseM.A. HermanW.H. HolmanR.R. JonesN.P. KravitzB.G. LachinJ.M. O’NeillM.C. ZinmanB. VibertiG. ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.N. Engl. J. Med.2006355232427244310.1056/NEJMoa06622417145742
     [Google Scholar]
  10. Lobeglitazone sulfate.Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Lobeglitazone-sulfate
  11. Lobeglitazone: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB09198
  12. BaeJ. ParkT. KimH. LeeM. ChaB.S. Lobeglitazone: A novel thiazolidinedione for the management of type 2 diabetes mellitus.Diabetes Metab. J.202145332633610.4093/dmj.2020.027233866775
     [Google Scholar]
  13. JangJ.Y. BaeH. LeeY.J. ChoiY.I. KimH.J. ParkS.B. SuhS.W. KimS.W. HanB.W. Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on PPARγ.Sci. Rep.2018813110.1038/s41598‑017‑18274‑129311579
     [Google Scholar]
  14. Glenmark launches lobeglitazone in India to treat type 2 diabetes in adults.Available from: http://www.pharmabiz.com/ArticleDetails.aspx?aid=153667&sid=13
  15. Akums receives DCGI approval for type 2 diabetes drug to improve insulin resistance.Available from: https://www.biospectrumindia.com/news/73/22593/akums-receives-dcgi-approval-for-type-2-diabetes-drug-to-improve-insulin-resistance.html
  16. VulichiS.R. KabraA. KumarR. SumanK. RaoC.V. Cruz-MartinsN. Concise perspectives on some synthetic thiazolidine-2,4-dione derivatives and their specific pharmacodynamic aspects.Life Sci.202127111918210.1016/j.lfs.2021.11918233577851
     [Google Scholar]
  17. LeeY. KimJ.H. KimS.R. JinH.Y. RheeE.J. ChoY.M. LeeB.W. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: Its efficacy and predictive factors related to responsiveness.J. Korean Med. Sci.2017321606910.3346/jkms.2017.32.1.6027914133
     [Google Scholar]
  18. LeeM.A. TanL. YangH. ImY.G. ImY.J. Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.Sci. Rep.2017711683710.1038/s41598‑017‑17082‑x29203903
     [Google Scholar]
  19. ChengD. GaoH. LiW. Long-term risk of rosiglitazone on cardiovascular events - A systematic review and meta-analysis.Endokrynol. Pol.201869438139429952413
     [Google Scholar]
  20. YanH. XieH. YingY. LiJ. WangX. XuX. ZhengX. Pioglitazone use in patients with diabetes and risk of bladder cancer: A systematic review and meta-analysis.Cancer Manag. Res.2018101627163810.2147/CMAR.S16484029970962
     [Google Scholar]
  21. TsengC.H. TsengF.H. Peroxisome proliferator-activated receptor agonists and bladder cancer: Lessons from animal studies.J. Environ. Sci. Health Part C Environ. Carcinog. Ecotoxicol. Rev.201230436840210.1080/10590501.2012.73551923167631
     [Google Scholar]
  22. Health ministry bans two drugs Analgin and Pioglitazone; Industry protests - The Economic Times.Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/health-ministry-bans-two-drugs-analgin-and-pioglitazone-industry-protests/articleshow/20789862.cms
  23. Withdrawal of rosiglitazone-containing medicines from South African market | South African Government.Available from: https://www.gov.za/news/media-statements/withdrawal-rosiglitazone-containing-medicines-south-african-market-05-jul
  24. Avandia banned in the UK.Available from: https://www.diabetes.co.uk/newsletter/forum-update-159/
  25. Drugs Banned In India.Available from: https://web.archive.org/web/20150221053621/http://cdsco.nic.in/html/drugsbanned.html
  26. Diabetes drug withdrawn.Available from: https://web.archive.org/web/20131013121141/http://www.stuff.co.nz/4669573
  27. KimB.Y. KwonH.S. KimS.K. NohJ.H. ParkC.Y. ParkH.K. SongK.H. WonJ.C. YuJ.M. LeeM.Y. LeeJ.H. LimS. ChunS.W. JeongI.K. ChungC.H. HanS.J. KimH.S. MinJ.Y. KimS. A real-world study of long-term safety and efficacy of lobeglitazone in Korean patients with type 2 diabetes mellitus.Diabetes Metab. J.202246685586510.4093/dmj.2021.026435255547
     [Google Scholar]
  28. DuttaD. BhattacharyaS. KumarM. DattaP.K. MohindraR. SharmaM. Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis.Diabetes Metab. Syndr.202317110269710.1016/j.dsx.2022.10269736580702
     [Google Scholar]
  29. GangopadhyayK.K. SinghA.K. Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal.Diabetes Metab. Syndr.202317410274710.1016/j.dsx.2023.10274736966544
     [Google Scholar]
  30. ChoungS. JoungK.H. YouB.R. ParkS.K. KimH.J. KuB.J. Treatment with Lobeglitazone attenuates Hepatic steatosis in diet-induced obese mice.PPAR Res.201820181810.1155/2018/429250930008738
     [Google Scholar]
  31. MoonK.S. LeeJ.E. LeeH.S. HwangI.C. KimD.H. ParkH.K. ChoiH.J. JoW. SonW.C. YunH.I. CKD‐501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks.J. Appl. Toxicol.201434121271128410.1002/jat.291824026970
     [Google Scholar]
  32. LeeH.S. ChangM. LeeJ.E. KimW. HwangI.C. KimD.H. ParkH.K. ChoiH.J. JoW. ChaS.W. SonW.C. Carcinogenicity study of CKD-501, a novel dual peroxisome proliferator-activated receptors α and γ agonist, following oral administration to Sprague Dawley rats for 94–101weeks.Regul. Toxicol. Pharmacol.201469220721610.1016/j.yrtph.2014.04.00324747398
     [Google Scholar]
  33. NissenS.E. WolskiK. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N. Engl. J. Med.2007356242457247110.1056/NEJMoa07276117517853
     [Google Scholar]
  34. LiaoH.W. SaverJ.L. WuY.L. ChenT.H. LeeM. OvbiageleB. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis.BMJ Open201771e01392710.1136/bmjopen‑2016‑01392728057658
     [Google Scholar]
  35. RizosC.V. ElisafM. MikhailidisD.P. LiberopoulosE.N. How safe is the use of thiazolidinediones in clinical practice?Expert Opin. Drug Saf.200981153210.1517/1474033080259782119236215
     [Google Scholar]
  36. KimS.G. KimD.M. WooJ.T. JangH.C. ChungC.H. KoK.S. ParkJ.H. ParkY.S. KimS.J. ChoiD.S. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: A multicenter, randomized, double-blind, parallel-group, placebo controlled trial.PLoS One201494e9284310.1371/journal.pone.009284324736628
     [Google Scholar]
  37. KimS.H. KimS.G. KimD.M. WooJ.T. JangH.C. ChungC.H. KoK.S. ParkJ.H. ParkY.S. KimS.J. ChoiD.S. Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study.Diabetes Res. Clin. Pract.20151103e27e3010.1016/j.diabres.2015.09.00926458774
     [Google Scholar]
  38. FloydJ.S. BarbehennE. LurieP. WolfeS.M. Case series of liver failure associated with rosiglitazone and pioglitazone.Pharmacoepidemiol. Drug Saf.200918121238124310.1002/pds.180419623674
     [Google Scholar]
  39. ParkJ. KimC.O. OhE.S. LeeJ.I. KimJ.K. AhnS.H. KimD.Y. KimS.U. KimB.K. ChungY.E. KimS. ParkM.S. Effects of hepatic impairment on the pharmacokinetic profile and safety of lobeglitazone.Clin. Pharmacol. Drug Dev.202211557658410.1002/cpdd.104535255191
     [Google Scholar]
  40. JoshiS. TandonM. KodguleR. WuW. JadhaoV. SuryawanshiS. BarkateH. Randomized, double-blind, phase III trial of lobeglitazone add-on to metformin in type 2 diabetes (Sensitize India).J. Assoc. Physicians India2024721324210.59556/japi.71.044538736072
     [Google Scholar]
  41. Pharmaceutical composition comprising metformin and lobeglitazone.Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=MY212731509&_cid=P21-LOZVVG-28401-1
  42. Pharmaceutical compositions comprising lobeglitazone for oral administration.Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=ID210119687&_cid=P21-LP01X3-04979-1
  43. Controlled release pharmaceutical formulation comprising lobeglitazone and metformin.Patent KR102070104B1,2018
  44. Composition for treating ophthalmic diseases comprising lobeglitazone as active ingredient.Patent KR1020220137542,
  45. Process for preparation of lobeglitazone or salt thereof.Patent IN202121002745,
  46. Pharmaceutical composition comprising lobeglitazone sulfate and its combination.Patent IN202121028279,
  47. LeeH. KimB. AhnJ. KangS. LeeJ. ShinJ. AhnS. LeeS. YoonS. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione.Eur. J. Med. Chem.200540986287410.1016/j.ejmech.2005.03.01915908051
     [Google Scholar]
  48. MottinM. SouzaP.C.T. SkafM.S. Molecular recognition of PPARγ by kinase Cdk5/p25: Insights from a combination of protein–protein docking and adaptive biasing force simulations.J. Phys. Chem. B2015119268330833910.1021/acs.jpcb.5b0426926047365
     [Google Scholar]
  49. LeeH.W. AhnJ.B. KangS.K. AhnS.K. HaD.C. Process development and scale-up of PPAR α/γ dual agonist lobeglitazone sulfate (CKD-501).Org. Process Res. Dev.200711219019910.1021/op060087u
     [Google Scholar]
  50. WillsonT.M. CobbJ.E. CowanD.J. WietheR.W. CorreaI.D. PrakashS.R. BeckK.D. MooreL.B. KliewerS.A. LehmannJ.M. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones.J. Med. Chem.199639366566810.1021/jm950395a8576907
     [Google Scholar]
  51. MomoseY. MeguroK. IkedaH. HatanakaC. OiS. SohdaT. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds.Chem. Pharm. Bull.19913961440144510.1248/cpb.39.14401934164
     [Google Scholar]
  52. DeFronzoR.A. FerranniniE. GroopL. HenryR.R. HermanW.H. HolstJ.J. HuF.B. KahnC.R. RazI. ShulmanG.I. SimonsonD.C. TestaM.A. WeissR. Type 2 diabetes mellitus.Nat. Rev. Dis. Primers2015111501910.1038/nrdp.2015.1927189025
     [Google Scholar]
  53. LebovitzH.E. Thiazolidinediones: The forgotten diabetes medications.Curr. Diab. Rep.2019191215110.1007/s11892‑019‑1270‑y31776781
     [Google Scholar]
  54. RizosC.V. KeiA. ElisafM.S. The current role of thiazolidinediones in diabetes management.Arch. Toxicol.20169081861188110.1007/s00204‑016‑1737‑427165418
     [Google Scholar]
  55. KahnC.R. ChenL. CohenS.E. Unraveling the mechanism of action of thiazolidinediones.J. Clin. Invest.2000106111305130710.1172/JCI1170511104782
     [Google Scholar]
  56. HaunerH. The mode of action of thiazolidinediones.Diabetes Metab. Res. Rev.200218S2S10S1510.1002/dmrr.24911921433
     [Google Scholar]
  57. DayC. Thiazolidinediones: A new class of antidiabetic drugs.Diabet. Med.199916317919210.1046/j.1464‑5491.1999.00023.x10227562
     [Google Scholar]
  58. ChoiBH JinZ Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice.PLoS One201813
     [Google Scholar]
  59. KimK.M. JinH.J. LeeS.Y. MaengH.J. LeeG.Y. OhT.J. ChoiS.H. JangH.C. LimS. Effects of lobeglitazone, a new thiazolidinedione, on osteoblastogenesis and bone mineral density in mice.Endocrinol. Metab.201732338939510.3803/EnM.2017.32.3.38928956370
     [Google Scholar]
  60. LimS. KimK.M. KimS.G. KimD.M. WooJ.T. ChungC.H. KoK.S. ParkJ.H. ParkY. KimS.J. JangH.C. ChoiD.S. Effects of lobeglitazone, a novel thiazolidinedione, on bone mineral density in patients with type 2 diabetes mellitus over 52 weeks.Diabetes Metab. J.201741537738510.4093/dmj.2017.41.5.37729086536
     [Google Scholar]
  61. LawR.E. GoetzeS. XiX.P. JacksonS. KawanoY. DemerL. FishbeinM.C. MeehanW.P. HsuehW.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells.Circulation2000101111311131810.1161/01.CIR.101.11.131110725292
     [Google Scholar]
  62. BaeK.H. SeoJ.B. JungY.A. SeoH.Y. KangS.H. JeonH.J. LeeJ.M. LeeS. KimJ.G. LeeI.K. JungG.S. ParkK.G. Lobeglitazone, a novel peroxisome proliferator-activated receptor γ agonist, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice.Endocrinol. Metab.201732111512310.3803/EnM.2017.32.1.11528256116
     [Google Scholar]
  63. LeeJ.H. NohC.K. YimC.S. JeongY.S. AhnS.H. LeeW. kimD.D. ChungS.J. Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats.J. Pharm. Sci.201510493049305910.1002/jps.2437825648999
     [Google Scholar]
  64. KimJ.W. KimJ.R. YiS. ShinK.H. ShinH.S. YoonS.H. ChoJ.Y. KimD.H. ShinS.G. JangI.J. YuK.S. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: A single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.Clin. Ther.201133111819183010.1016/j.clinthera.2011.09.02322047812
     [Google Scholar]
  65. KimY.K. HwangJ.G. ParkM.K. No relevant pharmacokinetic drug–drug interaction between the sodium-glucose co-transporter-2 inhibitor empagliflozin and lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, in healthy subjects.Drug Des. Devel. Ther.2021151725173410.2147/DDDT.S30221533953542
     [Google Scholar]
  66. ParkM.K. KimT.E. KimJ. KimC. YoonS.H. ChoJ.Y. JangI.J. YuK.S. LimK.S. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.Clin. Drug Investig.2014347467474https://link.springer.com/article/10.1007/s40261-014-0197-y10.1007/s40261‑014‑0197‑y24802657
     [Google Scholar]
  67. LeeY.S. ParkJ.S. LeeD.H. LeeD.K. KwonS.W. LeeB.W. BaeS.H. The antidiabetic drug lobeglitazone protects mice from lipogenesis-induced liver injury via mechanistic target of rapamycin complex 1 inhibition.Front. Endocrinol.2018953910.3389/fendo.2018.0053930298052
     [Google Scholar]
  68. LeeJ.H. WooY.A. HwangI.C. KimC.Y. KimD.D. ShimC.K. ChungS.J. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies.J. Pharm. Biomed. Anal.200950587287710.1016/j.jpba.2009.06.00319577404
     [Google Scholar]
  69. KimB. ShinH.S. KimJ.R. LimK.S. YoonS.H. YuK.S. ShinS-G. JangI-J. ChoJ-Y. Quantitative and qualitative analysis of CKD-501, lobeglitazone, in human plasma and urine using LC–MS/MS and its application to a pharmacokinetic study.Chromatographia20127511-1267167710.1007/s10337‑012‑2238‑0
     [Google Scholar]
  70. LeeJ.H. AhnS.H. MaengH.J. LeeW. KimD.D. ChungS.J. The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in rats.J. Pharm. Biomed. Anal.201511537538210.1016/j.jpba.2015.07.04026275726
     [Google Scholar]
  71. GulhaneP.D. JawarkarS.G. Bioanalytical method development and validation for determination of lobeglitazone in human plasma.Int. Res. J. Modernization Eng. Tech. Sci.20245581038116
     [Google Scholar]
  72. MudaliarS. SharmaS. Quantification of lobeglitazone sulfate in bulk and tablet dosage form by a validated uv spectroscopy method: A new thiazolidinedione anti-diabetic drug.Drug Metab. Bioanal. Lett.20241710.2174/0118723128319462240614111627
     [Google Scholar]
  73. PatelD. DobariyaJ. PradhanP. PatelG. MeshramD. Development and validation of UV Spectrophotometric methods for simultaneous estimation of Lobeglitazone sulfate and glimepiride in combined dosage form.Drug Anal. Res.202486269
     [Google Scholar]
  74. MahajanB. MiniyarP. ChodankarR. MahajanA. Liquid chromatography and liquid chromatography coupled with tandem mass spectrometry studies for the identification and characterization of degradation products of lobeglitazone.Sep Sci Plus20247e20230022310.1002/sscp.202300223
     [Google Scholar]
  75. SaiK.E.K. SrinivasM. KumariB.U. SumalathaC. MadhaviA. Development and validation of an HPLC method for the determination of lobeglitazone in bulk and in tablet formulation.Int. J. Pharm. Investig.202414204
     [Google Scholar]
  76. PatilMS Vijay PatilG JainAS Vijay HadalS Abhay PandeyA Sri Sesha Sai SwaroopN Liquid chromatographic-estimation of lobeglitazone sulphate in bulk and marketed formulation.AFJBS202461430013018
     [Google Scholar]
  77. SenA.K. SarkarT. SenD.B. MaheshwariR.A. ZanwarA.S. DumpalaR.L. Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high-performance thin layer chromatographic method.Sep Sci Plus20247e20240005910.1002/sscp.202400059
     [Google Scholar]
/content/journals/cac/10.2174/0115734110331672241216040932
Loading
Insights into the Chemistry, Pharmacokinetics and Analytical Techniques of Lobeglitazone: A Novel Anti-diabetic Drug
Current Analytical Chemistry 22, 185 (2026); https://doi.org/10.2174/0115734110331672241216040932
/content/journals/cac/10.2174/0115734110331672241216040932
/content/journals/cac/10.2174/0115734110331672241216040932
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): bioanalytical method; diabetes; Lobeglitazone; pharmacokinetics; synthesis; thiazolidinedione

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test